Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.
about
The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesRecent developments in receptor tyrosine kinases targeted anticancer therapyFGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical SignaturesFGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerA genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in JapaneseMsx homeobox genes critically regulate embryo implantation by controlling paracrine signaling between uterine stroma and epithelium.A predictive framework for integrating disparate genomic data types using sample-specific gene set enrichment analysis and multi-task learningSignalling pathways implicated in early mammary gland morphogenesis and breast cancer.Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.Differential fibroblast growth factor 8 (FGF8)-mediated autoregulation of its cognate receptors, Fgfr1 and Fgfr3, in neuronal cell linesVariation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer.N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties.Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Stroma regulates increased epithelial lateral cell adhesion in 3D culture: a role for actin/cadherin dynamicsA structure-guided approach to creating covalent FGFR inhibitorsA study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North IndiaErbB2 stabilizes epidermal growth factor receptor (EGFR) expression via Erk and Sprouty2 in extracellular matrix-detached cellsDifferential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growthCommon low-penetrance risk variants associated with breast cancer in Polish women.FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors.The FGF-1-specific single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis.Aryl Extensions of Thienopyrimidinones as Fibroblast Growth Factor Receptor 1 Kinase Inhibitors.Rationale for targeting fibroblast growth factor receptor signaling in breast cancerBioengineering embryonic stem cell microenvironments for the study of breast cancerFibroblast growth factor 9 (FGF9)-pituitary homeobox 2 (PITX2) pathway mediates transforming growth factor β (TGFβ) signaling to regulate cell proliferation in palatal mesenchyme during mouse palatogenesis.Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells.Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancerFibroblast growth factor family aberrations in cancers: clinical and molecular characteristicsGenome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.Myeloproliferative disorders: the centrosome connection.Antiangiogenic platinum through glycan targeting.FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs.Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancerVariation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.
P2860
Q24602570-0EA02FF5-8617-432E-BDAB-EA069AB2079DQ26751274-7DC5A260-C86C-402D-A97B-185C9BB2D8F0Q26751331-5500F726-9002-4B94-B36F-1B20BC21BEFCQ27684227-46A63412-C0C1-4B41-BBFC-8AB22AF45078Q27851554-E256062C-E4FF-4777-9100-3B718B604B1EQ28943445-21DEF1BA-ED67-4453-B127-12292A0568D4Q30428181-13D78027-D922-473F-8D39-F7D455BC8786Q30571667-99A63E52-E62E-41C2-B586-BBA4495AEF7BQ33255332-FCB620CC-5395-44DB-927D-77363C4783D8Q33330327-95A731DB-109D-4E7E-92A9-CE2E3ECFFC34Q33394535-4489EFD3-25C7-4D34-B1B7-AA23DF26763BQ33559912-857FF404-F681-4613-BB74-C003E9CF941FQ33590989-E089F8DB-022B-455D-BCFE-CC6E1D8254B9Q33734993-7335FD15-CF8C-4437-865B-701B6F55E3C8Q33751398-DE1320A6-C54A-4319-8835-328D19FBAC3CQ33886474-C0DBD528-4BA3-4F81-848F-44D0D3CDA24FQ34061522-31D9D003-BC73-4CD6-B4C7-C4698ECEE99AQ34379582-5C7353BD-753B-4B87-B3D5-928848715765Q34452774-065BBB43-EAA9-46F7-82CC-01ABB01F2879Q34490810-F6B60C6F-1BD8-458E-95C4-C54F3FAFD341Q34493797-E9ECDFCE-FF78-4E98-A8DE-97114808BD0BQ34551122-0E3417A0-1AA9-48D5-BC84-39EE6C9757E8Q34571563-C284AD97-AFE0-4837-B8AA-20DBABB468AEQ34812867-33FA8E09-67B5-4027-95FF-443BF3F8B664Q35131258-82AE84BA-6323-499E-B7A8-4A44C4DED298Q35600151-D46B51CA-07C9-41DB-9724-0275D7539387Q35709763-FF4CA6A9-EC60-4D97-BC5D-5010F4EE98DAQ35784682-3D141036-B0E1-44C0-BFE7-C7EB2D078A3CQ36008214-5AF549A5-7E52-45EC-8171-45DC5D0E98C0Q36161541-19F8FA8F-3E69-4C21-ACA2-A81A0420DB2FQ36189141-366A407C-7B97-4344-BA3E-19108825112EQ36227599-673A4224-646A-43C7-A9D6-C2FEFE0DBBF4Q36233843-9831584D-10E5-48BC-90FB-ED7CEF23C6ACQ36357296-FC4AA0E5-9E23-4FAF-9565-5934435CFF1CQ36524946-1D50E130-6AEB-4D07-895A-46DC736C4224Q36872440-94ED4DCD-AD24-4FD7-8EF4-1503B5F7EB89Q36938939-61E6B0AB-9CCC-4FD0-8632-9B7CB024B120Q37292711-0F3AB463-8448-4E19-B1DF-84A92B59FE64Q37389768-E4C0BA15-BFF6-4E6E-9E69-A9A29A310BB4Q37438789-9B004A66-C000-4167-A005-E0005FCA093C
P2860
Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Blocking of FGFR signaling inh ...... nregulation of D-type cyclins.
@en
Blocking of FGFR signaling inh ...... nregulation of D-type cyclins.
@nl
type
label
Blocking of FGFR signaling inh ...... nregulation of D-type cyclins.
@en
Blocking of FGFR signaling inh ...... nregulation of D-type cyclins.
@nl
prefLabel
Blocking of FGFR signaling inh ...... nregulation of D-type cyclins.
@en
Blocking of FGFR signaling inh ...... nregulation of D-type cyclins.
@nl
P2093
P2860
P356
P1433
P1476
Blocking of FGFR signaling inh ...... nregulation of D-type cyclins.
@en
P2093
Magdalena Koziczak
Nancy E Hynes
Thomas Holbro
P2860
P2888
P304
P356
10.1038/SJ.ONC.1207331
P407
P577
2004-04-01T00:00:00Z